Thalys(SH:603716) Sou Hu Cai Jing·2025-07-04 09:54Group 1 - The core viewpoint of the article highlights the recent surge in the stock price of Sairui Medical, which has experienced a consecutive four-day limit-up, attributed to increased market attention on innovative drug businesses [1] - Sairui Medical has invested in Huajiyuan Biotechnology, holding a 15.61% stake with an investment amount of 10.66 million yuan. The revenue for Huajiyuan Biotechnology in 2024 is projected to be 2.68 million yuan, with a net loss of 2.38 million yuan [1] - The therapeutic antihypertensive vaccine project HJY-ATRQβ-001 has completed concept verification and preclinical research, with the clinical trial application accepted by the National Medical Products Administration on June 6, 2025. However, the project still requires Phase I and Phase II clinical trials, with significant uncertainty regarding the success of these trials [1][2] Group 2 - The therapeutic antihypertensive vaccine is categorized as a global innovative therapy, addressing the large and growing demand for hypertension treatment. If successful, it will provide a new option for hypertension management [2] - The article emphasizes the long development cycle and uncertainty associated with new drug research and development, urging investors to recognize the risk characteristics of innovative drug development and to approach investment opportunities with caution [2]